Over the past year, there has been increased antitrust scrutiny in the U.K. and EU of pharmaceutical pricing, pricing negotiations with health authorities and supply practices. Georgios Zacharodimos provides an overview of decisions that find an excessive price infringement and explains authorities’ methodology in identifying exorbitant and unfair pricing.
An extract from GCR’s The Guide to Life Sciences – Third Edition. The whole publication is available at https://globalcompetitionreview.com/guide/guide-life-sciences.